| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 63 | 2025 | 290 | 19.040 |
Why?
|
| Coronary Occlusion | 33 | 2023 | 39 | 12.990 |
Why?
|
| Myocardial Infarction | 21 | 2025 | 351 | 8.660 |
Why?
|
| Treatment Outcome | 106 | 2025 | 2402 | 6.920 |
Why?
|
| ST Elevation Myocardial Infarction | 15 | 2025 | 36 | 6.520 |
Why?
|
| Transcatheter Aortic Valve Replacement | 19 | 2024 | 57 | 5.950 |
Why?
|
| Hospital Mortality | 30 | 2025 | 157 | 4.130 |
Why?
|
| Aortic Valve Stenosis | 17 | 2024 | 85 | 4.120 |
Why?
|
| Drug-Eluting Stents | 7 | 2022 | 102 | 4.100 |
Why?
|
| Risk Factors | 54 | 2025 | 2111 | 3.770 |
Why?
|
| Shock, Cardiogenic | 10 | 2025 | 18 | 3.760 |
Why?
|
| Coronary Restenosis | 8 | 2025 | 21 | 3.600 |
Why?
|
| Angioplasty, Balloon, Coronary | 7 | 2023 | 52 | 3.500 |
Why?
|
| Coronary Artery Disease | 8 | 2021 | 218 | 3.310 |
Why?
|
| Humans | 145 | 2025 | 28585 | 3.280 |
Why?
|
| Coronary Angiography | 31 | 2025 | 150 | 2.880 |
Why?
|
| Chronic Disease | 31 | 2023 | 273 | 2.850 |
Why?
|
| Stroke | 6 | 2023 | 256 | 2.310 |
Why?
|
| Stents | 12 | 2025 | 121 | 2.130 |
Why?
|
| Brachytherapy | 4 | 2025 | 51 | 2.130 |
Why?
|
| Coated Materials, Biocompatible | 4 | 2020 | 24 | 1.920 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 4 | 2023 | 13 | 1.890 |
Why?
|
| Aged | 40 | 2025 | 5525 | 1.840 |
Why?
|
| Femoral Artery | 8 | 2023 | 58 | 1.830 |
Why?
|
| Heart Valve Prosthesis Implantation | 9 | 2024 | 64 | 1.830 |
Why?
|
| Heart-Assist Devices | 3 | 2024 | 30 | 1.820 |
Why?
|
| Time Factors | 26 | 2024 | 1600 | 1.780 |
Why?
|
| Vascular Closure Devices | 3 | 2023 | 5 | 1.640 |
Why?
|
| Catheterization, Peripheral | 4 | 2021 | 24 | 1.600 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2024 | 30 | 1.550 |
Why?
|
| Endovascular Procedures | 5 | 2021 | 71 | 1.530 |
Why?
|
| Ventricular Function, Left | 9 | 2024 | 112 | 1.500 |
Why?
|
| Observational Studies as Topic | 10 | 2022 | 54 | 1.470 |
Why?
|
| Retrospective Studies | 25 | 2025 | 2612 | 1.450 |
Why?
|
| Mitral Valve Insufficiency | 8 | 2024 | 43 | 1.400 |
Why?
|
| Coronary Artery Bypass | 7 | 2023 | 68 | 1.370 |
Why?
|
| Cardiac Catheters | 3 | 2020 | 10 | 1.360 |
Why?
|
| Coronary Vessels | 4 | 2023 | 153 | 1.280 |
Why?
|
| Diabetes Mellitus | 4 | 2021 | 215 | 1.280 |
Why?
|
| Pharmaceutical Preparations | 2 | 2020 | 48 | 1.260 |
Why?
|
| Brain Ischemia | 2 | 2020 | 87 | 1.240 |
Why?
|
| Pacemaker, Artificial | 2 | 2019 | 56 | 1.220 |
Why?
|
| Cardiovascular Agents | 2 | 2019 | 22 | 1.190 |
Why?
|
| Aortic Valve | 12 | 2023 | 92 | 1.190 |
Why?
|
| Registries | 18 | 2023 | 393 | 1.180 |
Why?
|
| Risk Assessment | 14 | 2021 | 622 | 1.160 |
Why?
|
| Female | 43 | 2025 | 15472 | 1.150 |
Why?
|
| Patient Readmission | 3 | 2025 | 107 | 1.120 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2025 | 5 | 1.110 |
Why?
|
| Male | 40 | 2025 | 13772 | 1.100 |
Why?
|
| Vascular Diseases | 3 | 2023 | 68 | 1.080 |
Why?
|
| Cardiac Catheterization | 10 | 2024 | 114 | 1.070 |
Why?
|
| Peripheral Arterial Disease | 5 | 2021 | 144 | 1.070 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2023 | 48 | 1.060 |
Why?
|
| Pulmonary Embolism | 6 | 2023 | 126 | 1.060 |
Why?
|
| Middle Aged | 27 | 2025 | 7310 | 1.050 |
Why?
|
| United States | 20 | 2025 | 2201 | 1.010 |
Why?
|
| Postoperative Complications | 10 | 2024 | 631 | 0.980 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2025 | 4 | 0.960 |
Why?
|
| Endocarditis, Bacterial | 1 | 2025 | 15 | 0.950 |
Why?
|
| Aortic Diseases | 1 | 2025 | 17 | 0.950 |
Why?
|
| Coronary Stenosis | 1 | 2025 | 20 | 0.950 |
Why?
|
| Endocarditis | 1 | 2025 | 20 | 0.940 |
Why?
|
| Atherectomy, Coronary | 3 | 2023 | 9 | 0.940 |
Why?
|
| Abscess | 1 | 2025 | 25 | 0.940 |
Why?
|
| Heart Failure | 6 | 2024 | 250 | 0.910 |
Why?
|
| Heart Valve Prosthesis | 4 | 2021 | 62 | 0.900 |
Why?
|
| Embolic Protection Devices | 2 | 2021 | 7 | 0.870 |
Why?
|
| Databases, Factual | 12 | 2025 | 265 | 0.870 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2023 | 389 | 0.840 |
Why?
|
| Myocardial Revascularization | 2 | 2022 | 14 | 0.830 |
Why?
|
| Atrial Fibrillation | 4 | 2022 | 402 | 0.820 |
Why?
|
| Catheter Ablation | 3 | 2021 | 223 | 0.820 |
Why?
|
| Shock | 1 | 2023 | 17 | 0.820 |
Why?
|
| Atherectomy | 2 | 2020 | 11 | 0.810 |
Why?
|
| Thrombolytic Therapy | 6 | 2023 | 39 | 0.800 |
Why?
|
| Aged, 80 and over | 19 | 2024 | 2045 | 0.800 |
Why?
|
| Bundle-Branch Block | 2 | 2020 | 29 | 0.790 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 33 | 0.770 |
Why?
|
| Radial Artery | 4 | 2023 | 21 | 0.750 |
Why?
|
| Mitral Valve | 6 | 2024 | 63 | 0.740 |
Why?
|
| Embolism | 1 | 2021 | 14 | 0.700 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 48 | 0.690 |
Why?
|
| Aorta | 1 | 2021 | 124 | 0.690 |
Why?
|
| Pulmonary Valve | 1 | 2021 | 14 | 0.680 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 9 | 0.670 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 32 | 0.660 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 1026 | 0.650 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 27 | 0.650 |
Why?
|
| Polymers | 1 | 2021 | 117 | 0.640 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.640 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2019 | 7 | 0.640 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.620 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.620 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 29 | 0.620 |
Why?
|
| Atrial Flutter | 1 | 2019 | 13 | 0.620 |
Why?
|
| Incidence | 5 | 2025 | 568 | 0.570 |
Why?
|
| Aminophylline | 1 | 2018 | 1 | 0.570 |
Why?
|
| Bradycardia | 1 | 2018 | 17 | 0.560 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 47 | 0.550 |
Why?
|
| Hypertension | 1 | 2020 | 309 | 0.540 |
Why?
|
| Radiation Exposure | 3 | 2023 | 17 | 0.530 |
Why?
|
| Stroke Volume | 6 | 2023 | 124 | 0.520 |
Why?
|
| Pyridazines | 1 | 2016 | 8 | 0.500 |
Why?
|
| Aneurysm, False | 1 | 2016 | 19 | 0.500 |
Why?
|
| Survival Rate | 3 | 2024 | 431 | 0.500 |
Why?
|
| Ticlopidine | 1 | 2016 | 34 | 0.490 |
Why?
|
| Granuloma, Pyogenic | 1 | 2015 | 3 | 0.480 |
Why?
|
| Sarcoma, Kaposi | 1 | 2015 | 8 | 0.480 |
Why?
|
| Thrombosis | 3 | 2021 | 150 | 0.460 |
Why?
|
| Equipment Design | 3 | 2021 | 218 | 0.450 |
Why?
|
| Recovery of Function | 4 | 2024 | 122 | 0.430 |
Why?
|
| HIV Infections | 1 | 2016 | 161 | 0.430 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 147 | 0.420 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2024 | 16 | 0.410 |
Why?
|
| Hemostatic Techniques | 3 | 2023 | 14 | 0.410 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2020 | 173 | 0.410 |
Why?
|
| Angina, Unstable | 2 | 2023 | 19 | 0.400 |
Why?
|
| Saphenous Vein | 3 | 2022 | 24 | 0.390 |
Why?
|
| Coronary Circulation | 3 | 2020 | 30 | 0.350 |
Why?
|
| Inpatients | 5 | 2022 | 60 | 0.340 |
Why?
|
| Organ Transplantation | 2 | 2021 | 13 | 0.340 |
Why?
|
| Minnesota | 2 | 2020 | 42 | 0.320 |
Why?
|
| Hospitals | 4 | 2023 | 77 | 0.310 |
Why?
|
| Severity of Illness Index | 4 | 2024 | 461 | 0.300 |
Why?
|
| Limb Salvage | 4 | 2021 | 21 | 0.280 |
Why?
|
| Cardiotonic Agents | 2 | 2018 | 28 | 0.280 |
Why?
|
| Fibrinolytic Agents | 3 | 2023 | 70 | 0.280 |
Why?
|
| Length of Stay | 3 | 2024 | 240 | 0.270 |
Why?
|
| Comorbidity | 4 | 2020 | 259 | 0.270 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2024 | 11 | 0.260 |
Why?
|
| Anticoagulants | 4 | 2021 | 295 | 0.260 |
Why?
|
| Ultrasonography, Interventional | 3 | 2023 | 39 | 0.250 |
Why?
|
| Hospitals, Teaching | 2 | 2023 | 26 | 0.250 |
Why?
|
| Vascular Surgical Procedures | 2 | 2023 | 54 | 0.240 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2025 | 17 | 0.240 |
Why?
|
| Age Factors | 4 | 2020 | 734 | 0.240 |
Why?
|
| Punctures | 3 | 2021 | 17 | 0.240 |
Why?
|
| Global Health | 1 | 2025 | 54 | 0.230 |
Why?
|
| Wrist | 2 | 2022 | 8 | 0.230 |
Why?
|
| Indigo Carmine | 2 | 2021 | 3 | 0.230 |
Why?
|
| Mortality | 2 | 2021 | 46 | 0.220 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2024 | 18 | 0.220 |
Why?
|
| Oxygen | 1 | 2025 | 234 | 0.220 |
Why?
|
| Vitamin K | 2 | 2021 | 39 | 0.220 |
Why?
|
| Dissection | 2 | 2020 | 20 | 0.210 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 44 | 0.210 |
Why?
|
| Collateral Circulation | 2 | 2020 | 12 | 0.210 |
Why?
|
| Hemorrhage | 5 | 2023 | 265 | 0.200 |
Why?
|
| Heart Arrest | 2 | 2020 | 27 | 0.200 |
Why?
|
| Blood Pressure | 1 | 2024 | 355 | 0.200 |
Why?
|
| Reoperation | 2 | 2021 | 153 | 0.200 |
Why?
|
| Radiation Dosage | 2 | 2020 | 54 | 0.200 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2023 | 21 | 0.200 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2023 | 45 | 0.200 |
Why?
|
| Ventricular Remodeling | 2 | 2024 | 32 | 0.200 |
Why?
|
| Postoperative Hemorrhage | 2 | 2020 | 32 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2020 | 47 | 0.200 |
Why?
|
| Conservative Treatment | 1 | 2022 | 11 | 0.200 |
Why?
|
| Vascular Patency | 2 | 2020 | 44 | 0.190 |
Why?
|
| Lithotripsy | 1 | 2022 | 9 | 0.190 |
Why?
|
| Blood Transfusion | 2 | 2020 | 77 | 0.190 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2021 | 163 | 0.190 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2022 | 43 | 0.190 |
Why?
|
| Thromboangiitis Obliterans | 1 | 2022 | 1 | 0.190 |
Why?
|
| Pericardial Effusion | 1 | 2022 | 12 | 0.180 |
Why?
|
| Pandemics | 2 | 2020 | 196 | 0.180 |
Why?
|
| Prospective Studies | 2 | 2023 | 1272 | 0.180 |
Why?
|
| Midwestern United States | 1 | 2021 | 39 | 0.180 |
Why?
|
| Atrial Appendage | 1 | 2022 | 32 | 0.180 |
Why?
|
| Water | 1 | 2022 | 135 | 0.180 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2021 | 1 | 0.180 |
Why?
|
| Bioprosthesis | 1 | 2021 | 21 | 0.170 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2021 | 5 | 0.170 |
Why?
|
| Thrombectomy | 1 | 2021 | 28 | 0.170 |
Why?
|
| Injections, Intravenous | 2 | 2018 | 66 | 0.170 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 34 | 0.170 |
Why?
|
| Prosthesis Design | 1 | 2021 | 88 | 0.170 |
Why?
|
| Transplant Recipients | 1 | 2020 | 12 | 0.170 |
Why?
|
| Electric Countershock | 1 | 2020 | 29 | 0.160 |
Why?
|
| Carotid Arteries | 1 | 2020 | 54 | 0.160 |
Why?
|
| Radiation Protection | 1 | 2020 | 17 | 0.160 |
Why?
|
| Hospitalization | 4 | 2023 | 199 | 0.160 |
Why?
|
| Lasers | 1 | 2020 | 67 | 0.160 |
Why?
|
| Vascular Calcification | 1 | 2020 | 20 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 180 | 0.160 |
Why?
|
| Occupational Exposure | 1 | 2020 | 28 | 0.160 |
Why?
|
| Heart Diseases | 1 | 2020 | 71 | 0.160 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2020 | 44 | 0.160 |
Why?
|
| Furosemide | 1 | 2019 | 7 | 0.160 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2019 | 1 | 0.160 |
Why?
|
| Ventricular Septal Rupture | 1 | 2019 | 1 | 0.160 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 26 | 0.160 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 55 | 0.160 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2019 | 26 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 98 | 0.160 |
Why?
|
| Heart Ventricles | 1 | 2020 | 139 | 0.160 |
Why?
|
| Recurrence | 1 | 2020 | 325 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 357 | 0.150 |
Why?
|
| Protective Factors | 1 | 2019 | 16 | 0.150 |
Why?
|
| Postoperative Period | 1 | 2019 | 68 | 0.150 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 480 | 0.150 |
Why?
|
| Heart | 1 | 2020 | 224 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 134 | 0.150 |
Why?
|
| Primary Prevention | 1 | 2019 | 25 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2019 | 64 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 93 | 0.150 |
Why?
|
| Catheterization | 1 | 2019 | 50 | 0.150 |
Why?
|
| Child, Preschool | 1 | 2022 | 1167 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 78 | 0.150 |
Why?
|
| Cardiac Output, Low | 1 | 2018 | 3 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2020 | 458 | 0.140 |
Why?
|
| Aspirin | 1 | 2019 | 125 | 0.140 |
Why?
|
| Catheters | 3 | 2023 | 24 | 0.140 |
Why?
|
| Electrocardiography | 1 | 2019 | 394 | 0.140 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2017 | 15 | 0.140 |
Why?
|
| Nitriles | 1 | 2016 | 33 | 0.120 |
Why?
|
| Ischemia | 3 | 2021 | 83 | 0.120 |
Why?
|
| Drug Interactions | 1 | 2016 | 79 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 191 | 0.120 |
Why?
|
| Acute Kidney Injury | 3 | 2021 | 74 | 0.120 |
Why?
|
| Quality of Life | 1 | 2019 | 504 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2016 | 128 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 373 | 0.110 |
Why?
|
| Sex Factors | 3 | 2022 | 467 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 378 | 0.110 |
Why?
|
| Adult | 3 | 2021 | 7922 | 0.100 |
Why?
|
| Acute Disease | 2 | 2022 | 155 | 0.090 |
Why?
|
| United States Food and Drug Administration | 2 | 2021 | 45 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2022 | 236 | 0.080 |
Why?
|
| Fluoroscopy | 2 | 2021 | 36 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2024 | 202 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2021 | 190 | 0.080 |
Why?
|
| Critical Illness | 2 | 2021 | 66 | 0.080 |
Why?
|
| Hemodynamics | 2 | 2019 | 221 | 0.070 |
Why?
|
| Animals | 1 | 2021 | 10583 | 0.060 |
Why?
|
| Microcirculation | 1 | 2025 | 113 | 0.060 |
Why?
|
| Cause of Death | 1 | 2024 | 73 | 0.060 |
Why?
|
| Hypotension | 1 | 2024 | 19 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2024 | 72 | 0.050 |
Why?
|
| Embolectomy | 1 | 2023 | 2 | 0.050 |
Why?
|
| Sutures | 1 | 2023 | 15 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2023 | 30 | 0.050 |
Why?
|
| Young Adult | 2 | 2020 | 2804 | 0.050 |
Why?
|
| Tricuspid Valve | 1 | 2022 | 31 | 0.050 |
Why?
|
| Hospitals, Low-Volume | 1 | 2021 | 3 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2021 | 78 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2022 | 172 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 24 | 0.040 |
Why?
|
| Needles | 1 | 2021 | 26 | 0.040 |
Why?
|
| Pancreas Transplantation | 1 | 2020 | 1 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 37 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2020 | 4 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 39 | 0.040 |
Why?
|
| Off-Label Use | 1 | 2020 | 6 | 0.040 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 1 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 3 | 0.040 |
Why?
|
| Cineangiography | 1 | 2020 | 8 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 7 | 0.040 |
Why?
|
| Anemia | 1 | 2020 | 43 | 0.040 |
Why?
|
| Dabigatran | 1 | 2020 | 20 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 13 | 0.040 |
Why?
|
| X-Rays | 1 | 2020 | 31 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 35 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2020 | 52 | 0.040 |
Why?
|
| Pyridones | 1 | 2020 | 36 | 0.040 |
Why?
|
| Rivaroxaban | 1 | 2020 | 29 | 0.040 |
Why?
|
| Hematoma | 1 | 2020 | 26 | 0.040 |
Why?
|
| Video Recording | 1 | 2020 | 40 | 0.040 |
Why?
|
| Patient Safety | 1 | 2020 | 38 | 0.040 |
Why?
|
| Thiazoles | 1 | 2020 | 50 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2020 | 56 | 0.040 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2019 | 4 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 70 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 22 | 0.040 |
Why?
|
| Pyridines | 1 | 2020 | 108 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 63 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 12 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2018 | 9 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2019 | 108 | 0.040 |
Why?
|
| Patient Selection | 1 | 2019 | 149 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 478 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 732 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 59 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2018 | 66 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 380 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2020 | 893 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 430 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2017 | 5 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 807 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 770 | 0.030 |
Why?
|
| Adolescent | 1 | 2018 | 3165 | 0.020 |
Why?
|